2319 A TMPRSS2:ERG GENE FUSION MOLECULAR URINE ASSAY CORRELATES WITH PATHOLOGIC STAGE AND PROSTATECTOMY GLEASON SCORE AND IS ASSOCIATED WITH BIOPSY-TO-PROSTATECTOMY GLEASON UPGRADING

Abstract

You have accessJournal of UrologyProstate Cancer: Markers1 Apr 20112319 A TMPRSS2:ERG GENE FUSION MOLECULAR URINE ASSAY CORRELATES WITH PATHOLOGIC STAGE AND PROSTATECTOMY GLEASON SCORE AND IS ASSOCIATED WITH BIOPSY-TO-PROSTATECTOMY GLEASON UPGRADING Alexander Haese, Felix Chun, Sarah Meyer, Sheila Aubin, John Day, and Jack Groskopf Alexander HaeseAlexander Haese Hamburg, Germany More articles by this author , Felix ChunFelix Chun Hamburg, Germany More articles by this author , Sarah MeyerSarah Meyer San Diego, CA More articles by this author , Sheila AubinSheila Aubin San Diego, CA More articles by this author , John DayJohn Day San Diego, CA More articles by this author , and Jack GroskopfJack Groskopf San Diego, CA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2566AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES An unmet need in PCa prognosis is the differentiation between indolent and significant PCa. Biochemical (e.g. PSA), clinical (e.g. clinical stage) or histological (BxGleason score) parameters, alone or combined, are not sufficiently accurate to aid in this critical distinction. On a genetic basis, a fusion between TMPRSS2 and the ETS family of transcription factors, found in 50–70% of PCa, is the most common specific gene rearrangement identified to date among solid human malignancies. Studies have linked PCa gene fusions to indicators of significant PCA. In this prospective, ongoing study, we evaluated the correlation of a prototype quantitative TMPRSS2:ERG (T2:ERG) gene fusion urine assay with outcomes in men with PCa scheduled for RRP. METHODS Post-DRE first-catch urine specimens were collected prior to RRP. T2:ERG mRNA copies were quantified using a transcription-mediated amplification assay and results normalized to PSA mRNA copies by calculating the ratio of TMPRSS2:ERG/PSA copies x 100,000 (T2:ERG Score). The prototype T2:ERG urine assay detects the gene fusion mRNA isoform corresponding to TMPRSS2 exon 1 to ERG exon 4. The T2:ERG Score was correlated with the presence or absence of pathologically organ (OC) vs. non-organ-confined (NOC) PCa and the presence or absence of Bx-to-RRP Gleason upgrading. RESULTS Of 74 subjects 28 (38%) had NOC-disease (≥pT3) and 69 (93%) had a RRP Gleason score ≥7. 21/26 subjects with BxGleason score of 6 were upgraded to Gleason Score ≥7 at RRP. Median T2:ERG Score was significantly higher in men with NOC vs. OC-PCa (80 vs. 9, p=0.002) and with RRP Gleason scores ≥7 vs. 6 (31 vs. 2, p=0.04). The median T2:ERG Score for subjects with vs without Bx-to-RRP-upgrading was 32 vs 2, respectively. CONCLUSIONS The T2:ERG assay correlated significantly with pT-stage and RRPGleason score. Interestingly, subjects with Bx-to-RRP-upgrading showed a trend towards higher median T2:ERG Scores. These data suggest that a T2:ERG urine assay may be useful to decide when more aggressive treatment of PCa is necessary. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e930 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alexander Haese Hamburg, Germany More articles by this author Felix Chun Hamburg, Germany More articles by this author Sarah Meyer San Diego, CA More articles by this author Sheila Aubin San Diego, CA More articles by this author John Day San Diego, CA More articles by this author Jack Groskopf San Diego, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...